Captrust Financial Advisors Has $1.51 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Captrust Financial Advisors lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 32.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,414 shares of the biopharmaceutical company's stock after acquiring an additional 1,581 shares during the period. Captrust Financial Advisors' holdings in Alnylam Pharmaceuticals were worth $1,509,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in ALNY. Beck Bode LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $13,181,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $612,000. Comerica Bank raised its holdings in shares of Alnylam Pharmaceuticals by 631.7% in the 4th quarter. Comerica Bank now owns 13,991 shares of the biopharmaceutical company's stock worth $3,292,000 after purchasing an additional 12,079 shares in the last quarter. Voleon Capital Management LP bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $8,749,000. Finally, Utah Retirement Systems raised its holdings in shares of Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Utah Retirement Systems now owns 21,325 shares of the biopharmaceutical company's stock worth $5,018,000 after purchasing an additional 400 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 2.3%

Alnylam Pharmaceuticals stock traded up $6.55 during trading hours on Monday, hitting $291.86. The company had a trading volume of 929,466 shares, compared to its average volume of 911,970. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The firm has a market capitalization of $38.06 billion, a P/E ratio of -134.50 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $146.79 and a fifty-two week high of $304.39. The firm's fifty day moving average is $254.72 and its 200-day moving average is $253.61.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. The firm's quarterly revenue was up 20.2% on a year-over-year basis. During the same period last year, the company earned ($0.16) earnings per share. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Citigroup boosted their target price on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Redburn Atlantic started coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a "buy" rating and a $353.00 target price on the stock. Needham & Company LLC restated a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, UBS Group boosted their price target on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have given a buy rating to the company's stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $319.17.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at $3,017,271.63. The trade was a 11.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the sale, the executive vice president now directly owns 12,881 shares of the company's stock, valued at $3,240,344.36. This represents a 10.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.